Citation data for Burke John E from google scholar

Citation data from Pubmed

Articles from UVic (trainees in italics)


45. An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. Masson GR, Jenkins ML, Burke JE. Expert Opin Drug Discov. 2017 Aug 3. doi: 10.1080/17460441.2017.1363734.

44. Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. McGregor LM, Jenkins ML, Kerwin C, Burke JE, Shokat KM. Biochemistry. 2017 Jun 27;56(25):3178-3183. doi: 10.1021/acs.biochem.7b00271.

43. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas. Siempelkamp BD, Rathinaswamy MK, Jenkins ML, Burke JE.
J Biol Chem. 2017 Jul 21;292(29):12256-12266. doi: 10.1074/jbc.M117.789263.

42. Novel PIK3CD mutations affecting N-terminal residues of p110δ cause APDS1 in humans. Takeda AJ, Zhang Y, Dornan GL, Siempelkamp BD, Jenkins ML, Matthews HF, McElwee JJ, Bi W, Seeborg FO, Su HC, Burke JE, Lucas CL. J Allergy Clin Immunol. 2017 Apr 13. pii: S0091-6749(17)30587-0.

41. Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Bohnacker T, Prota AE, Beaufils F, Burke JE, Melone A, Inglis AJ, Rageot D, Sele AM, Cmiljanovic V, Cmiljanovic N, Bargsten K, Aher A, Akhmanova A, Díaz JF, Fabbro D, Zvelebil M, Williams RL, Steinmetz MO, Wymann MP. Nat Commun. 2017 Mar 9;8:14683.

40. Conformational disruption of PI3Kδ regulation by primary immunodeficiency mutations in PIK3CD and PIK3R1. Dornan, GD, Siempelkamp, BD, Jenkins, ML, Vadas, O, Lucas, CL, Burke, JEProc Natl Acad Sci U S A. 2017 Feb 21;114(8):1982-1987.

39. Recognition of protein-linked glycans as a determinant of peptidase activity. Noach I, Ficko-Blean E, Pluvinage B, Stuart C, Jenkins ML, Brochu D, Buenbrazo N, Wakarchuk W, Burke JE, Gilbert M, Boraston AB. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E679-E688.

38. The Molecular Basis of Aichi Virus 3A Protein Activation of Phosphatidylinositol 4 Kinase IIIβ, PI4KB, through ACBD3. McPhail JA, Ottosen EH, Jenkins ML, Burke JE. Structure. 2017 Jan 3;25(1):121-131.

37. Using Hydrogen–Deuterium Exchange Mass Spectrometry to Examine Protein–Membrane Interactions. Vadas O, Jenkins ML, Dornan GLBurke JE. Methods in Enzymology. 2017;583:143-172.


33. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V, Clarke D, Derbyshire ER, Dornan G, Duffy S, Eckley S, Itoe MA, Koolen KM, Lewis TA, Lui PS, Lukens AK, Lund E, March S, Meibalan E, Meier BC, McPhail J, Mitasev B, Moss EL, Sayes M, VanGessel Y, Wawer MJ, Yoshinaga T, Zeeman AM, Avery VM, Bhatia SN, Burke JE, Catteruccia F, Clardy JC, Clemons PA, Dechering KJ, Duvall JR, Foley MA, Gusovsky F, Kocken CH, Marti M, Morningstar ML, Munoz B, Neafsey DE, Sharma A, Winzeler EA, Wirth DF, Scherer CA, Schreiber SL. Nature. 2016 Sep 7;538(7625):344-349.

32. Molecular basis for recognition of the cancer glycobiomarker LacdiNAc (GalNAc(β1-4)GlcNAc) by Wisteria floribunda agglutinin. Haji-Ghassemi O, Gilbert M, Spence J, Schur MJ, Parker MJ, Jenkins ML, Burke JE, van Faassen H, Young NM, Evans SV. J Biol Chem. 2016. 2016 Nov 11;291(46):24085-24095.

29. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. Rutaganira FU, Fowler ML, McPhail JA, Gelman MA, Nguyen K, Xiong A, Dornan GL, Tavshanjian B, Glenn JS, Shokat KM, Burke JE. J Med Chem. 2016 Mar 10;59(5):1830-9.

28. Type III phosphatidylinositol 4 kinases: structure, function, regulation, signalling and involvement in disease. Dornan GL, McPhail JA, Burke JEBiochem Soc Trans. 2016 Feb 15;44(1):260-6.

27. Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11. Fowler ML, McPhail JA, Jenkins ML, Masson GR, Rutaganira FU, Shokat KM, Williams RL, Burke JEProtein Sci. 2016 Apr;25(4):826-39.


24. Vadas O.Burke, J.E., 2015 Probing the regulation of membrane signalling complexes and their role in disease using hydrogen deuterium exchange mass spectrometry (HDX-MS). Invited review, Biochem Soc Trans. 2015 Oct;43(5):773-86.

23. Burke, J.E., Williams, R.L., 2015. Synergy in activating class I phosphoinositide 3 kinases. Invited featured review, Trends in Biochemical Sciences. 40 (2), 88-100.


Articles from postdoc and PhD training (trainees in italics)


36. Regulation of a Coupled MARCKS-PI3K Lipid Kinase Circuit by Calmodulin: Single-Molecule Analysis of a Membrane-Bound Signaling Module. Ziemba BP, Swisher GH, Masson G, Burke JE, Williams RL, Falke JJ. Biochemistry. 2016 Nov 22;55(46):6395-6405.

35. Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. Mevissen TE, Kulathu Y, Mulder MP, Geurink PP, Maslen SL, Gersch M, Elliott PR, Burke JE, van Tol BD, Akutsu M, El Oualid F, Kawasaki M, Freund SM, Ovaa H, Komander D. Nature. 2016 Oct 12;538(7625):402-405.

34. Characterization of Atg38 and NRBF2, a fifth subunit of the autophagic Vps34/PIK3C3 complex. Ohashi Y, Soler N, García Ortegón M, Zhang L, Kirsten ML, Perisic O, Masson GR, Burke JE, Jakobi AJ, Apostolakis AA, Johnson CM, Ohashi M, Ktistakis NT, Sachse C, Williams RL. Autophagy. 2016 Nov;12(11):2129-2144.

31. Regulation of PI3K by PKC and MARCKS: Single-Molecule Analysis of a Reconstituted Signaling Pathway. Ziemba BP, Burke JE, Masson G, Williams RL, Falke JJ. Biophys J. 2016 Apr 26;110(8):1811-25.

30. Methods in the Study of PTEN Structure: X-Ray Crystallography and Hydrogen Deuterium Exchange Mass Spectrometry. Masson GR, Burke JE, Williams RL. Methods Mol Biol. 2016;1388:215-30.

26. The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity. Masson GR, Perisic O, Burke JE, Williams RL. Biochem J. 2016 Jan 15;473(2):135-44.


25. Structure and flexibility of the endosomal Vps34 complex reveals the basis of its function on membranes. Rostislavleva K, Soler N, Ohashi Y, Zhang L, Pardon E, Burke JE, Masson GR, Johnson C, Steyaert J, Ktistakis NT, Williams RL. Science. 2015 Oct 9;350(6257):aac7365.


22. Clarke, J.H., Giudici, M.L.,Burke, J.E., Williams, R.L., Maloney, D.J., Marugan, J.J., Irvine, R.F, 2014. The function of phosphatidylinositol 5-phosphate 4-kinase γ           (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P binding site.      Biochemical journal. 466 (2), 359-367.

21. Burke J.E, Inglis, A.J., Perisic, O.,Masson, G.R., Mclaughlin, S., Rutaganira, F., Shokat, K.M., Williams, R.L., 2014. Structures of PI4KIIIß complexes reveal a mechanism for simultaneous recruitment of Rab11 and its effectors. Science. 344(6187), 1035-8.


20. Vadas, O., Dbouk, H.A., Shymanets, A., Perisic, O.,Burke J.E., Khali, B.D., Harteneck, C., Nurnberg, B., Backer, J.M., Williams, R.L. (2013) Molecular determinants of PI3Kγ-mediated chemotaxis and transformation downstream of GPCRs. Proceedings of the National Academy of Sciences, 110 (47), 18862-18867.

19. D’Angelo, G., Uemura, T., Chuang, C.C., Polishchuk, E., Santoro, M., Ohvo-Rekila, H., Sato, T., Di Tullio, G., Varriale, A., D’Auria, S., Daniele, T., Capuani, F., Johannes, L., Mattjus, P., Monti, M., Pucci, P., Williams, R.L.,Burke, J.E., Platt, F., Harada, A., De Matteis, M.A. (2013) Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi complex. Nature 01 (7465), 116-120.

18. Burke, J.E., Williams, R.L. (2013) Connecting with an old partner in a new way. Cancer cell, 23 (5), 559-561

17. Walser, R.,Burke, J.E., Gogvadze, E., Bohnacker, T.,Zhang, X., Hess, D., Küenzi, P., Leitges, M., Hirsch, E., Williams, R.L., Laffargue, M., Wymann, M.P. (2013) PKCβ Phosphorylates PI3Kγ to Activate it and Release it from GPCR Control. PLOS Biology, 11 (6), e1001587.

16. Burke, J.E., Perisic, O., Williams, R.L. Allosteric activation of PI3Kα by oncogenic mutations. (2013) Oncotarget 4 (2) 180-181 Cover article.

15. Cao, J.,Burke, J.E., and Dennis, E.A. Using Hydrogen-Deuterium Exchange Mass Spectrometry to Define the Specific Interactions of the Phospholipase A2 Superfamily with Lipid Substrates, Inhibitors and Membranes. (2013) Journal of Biological Chemistry 288 (3), 1806-1813.

14. Burke, J.E., Williams, R.L. (2013) Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Advances in Biological Regulation 53 (1) 97-110.


13. Dbouk H.A.,Vadas, O., Shymanets, A.,Burke, J.E., Salamon, R.S., Khalil, B.D., Perisic, O., Shepherd, P.R., Harteneck, C., Hardecover_expansionn, T.K., Smrcka, A.V., Taussig, R., Bresnick, A.R., Nürnberg, B., Williams, R.L., and Backer, J.M. (2012) GPCR-mediated activation of p110β via Gβγ is required for cell transformation and chemotaxis. Science signalling 5 (253), ra89 Cover article.

12. Burke, J.E., Perisic, O.,Masson, G.R., Vadas, O., and Williams R.L. (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proceedings of the National Academy of Sciences 109 (38), 15259-15264.


11. Vadas, O.,Burke J.E.,Zhang, X., Berndt, A., and Williams, R.L. (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Science signalling 4 (195).

10. Burke, J.E.,Vadas, O., Berndt, A., Finegan, T., Perisic, O., and Williams R.L. (2011) Dynamics of the Phosphoinositide 3-Kinase p110δ Interaction with p85α and Membranes Reveals Aspects of Regulation Distinct from p110α. Structure 19 (8):1127-37.


9. Kokotos, G., Hsu, Y.H.,Burke, J.E., Baskakis, C., Kokotos, C.G., Magrioti, V., and Dennis, E.A. (2010) Potent and selective flouroketone inhibitors of group VIA calcium-independent phospholipase A2. Journal of Medicinal Chemistry 53, 3602-3610.


8. Hsu, Y. H.,Burke, J.E., Li, S., Woods, V. L., Jr., and Dennis, E. A. (2009) Localizing the membrane binding region of Group VIA Ca2+-independent phospholipase A2 using peptide amide hydrogen/deuterium exchange mass spectrometry. Journal of Biological Chemistry 284, 23652-61.

7. Burke, J.E., Babakhani , A., Gorfe, A.A., Kokotos, G., Li, S., Woods, V.L., Jr., McCammon, J.A., and Dennis, E.A. (2009) Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. Journal of the American Chemical Society 131, 8083-91.

6. Burke, J.E., Dennis, E.A. (2009) Phospholipase A2Structure/Function and Signaling. Journal of Lipid Research 50, Suppl:S237-42.Most cited paper in Journal of Lipid Research (2008-2013).

5. Burke, J.E., Dennis, E.A. (2009) Phospholipase A2Biochemistry. Cardiovascular drugs and therapy 23, 49-59.

4. Prévost, N., Mitsios, J.V., Kato, H.,Burke, J.E., Dennis, E.A., Shimizu, T., and Shattil, S.J. (2009) Cytosolic Phospholipase A2 α (cPLA2α) and Integrin αIIbβ3 Reinforce Each Other’s Functions During αIIbβ3 Signaling in Platelets. Blood 113, 447-57.


3. Burke, J.E., Hsu, Y.H., Deems, R.A., Li, S., Woods, V.L., Jr., and Dennis E.A. (2008) A Phospholipid Substrate Molecule Residing in the Membrane Surface Mediates Opening of the Lid Region in Group IVA Cytosolic Phospholipase A2. Journal of Biological Chemistry 283, 31227-36.

2. Burke, J.E., Karbarz, M.J., Deems, R.A., Li, S., Woods, V.L., Jr., and Dennis, E.A. (2008) Interaction of group IA phospholipase A2 with metal ions and phospholipid vesicles probed with deuterium exchange mass spectrometry, Biochemistry 47, 6451-6459.

1. Hsu, Y. H.,Burke, J.E., Stephens, D.L., Deems, R.A., Li, S., Asmus, K.M., Woods, V.L., Jr., and Dennis, E.A. (2008) Calcium binding rigidifies the C2 domain and the intra-domain interaction of GIVA phospholipase A2 as revealed by hydrogen/deuterium exchange mass spectrometry, Journal of Biological Chemistry 283, 9820-9827.